Shricon Industries reported a strong turnaround for FY2025-26, moving from a loss to a profit of ₹1.48 crore on a revenue of ₹4.03 crore. The company also acquired a drug license to trade in pharmaceuticals via its e-commerce platform.
Shricon Industries Reports Strong FY26 Turnaround
Shricon Industries reported a significant financial turnaround for the year ended March 31, 2026. Total Revenue (Gross): ₹4.03 crore (₹403.39 lakh) Profit After Tax: ₹1.48 crore (₹147.84 lakh) Reader Takeaway: Profitability achieved; diversification into pharma trading via e-commerce adds a new avenue. ## What just happened Shricon Industries announced its financial results for the fiscal year 2025-26, showcasing a substantial improvement. The company posted a gross revenue of ₹4.03 crore, a 585% increase from ₹0.59 crore in the previous fiscal year. Crucially, Shricon Industries successfully transitioned from a net loss of ₹0.15 crore in FY 2024-25 to a net profit of ₹1.48 crore in FY 2025-26. ## Why this matters This financial performance is significant as it marks a successful recovery from a loss-making position. The substantial revenue growth indicates improved operational performance or market traction. Furthermore, the acquisition of a drug license on July 15, 2025, allows the company to enter the pharmaceutical and healthcare trading business through its existing e-commerce platform, signalling a strategic diversification effort. ## The backstory The company's operations are currently centered around real estate and e-commerce services. The acquisition of the drug license is a recent strategic move, not yet a core part of its historical operations, but it opens up a new segment for the company's e-commerce arm. ## What changes now Shricon Industries will now be able to trade in pharmaceutical and healthcare products. The company has also appointed M/s Birla and Associates as new Statutory Auditors for a five-year term, filling a vacancy. Several board changes occurred, including the appointment of an Executive Director and CFO. Proposed inter-corporate loans and related party transactions for FY 2026-27 are subject to shareholder approval. ## Risks to watch The company has proposed inter-corporate loans totaling ₹30 crore to CP Capital Limited and Sankalp Capital Private Limited, entities with common directors. This significant allocation to related parties is a watch point for governance and fund utilization. Additionally, management has included a disclaimer regarding forward-looking statements, acknowledging potential risks from economic fluctuations and supply chain volatility. ## Peer comparison Information on specific peers and their recent financial performance is not provided in the filing. Shricon Industries' reported profit of ₹1.48 crore and revenue of ₹4.03 crore for FY26 are key metrics for future comparisons within its operational segments. ## Context metrics (time-bound) * **FY 2025-26 Gross Income:** ₹4.03 crore (₹403.39 lakh) * **FY 2024-25 Gross Income:** ₹0.59 crore (₹58.83 lakh) * **Change in Gross Income:** +585% * **FY 2025-26 Profit After Tax:** ₹1.48 crore (₹147.84 lakh) * **FY 2024-25 Profit After Tax:** (₹0.15 crore) ((₹14.83 lakh)) * **Auditor Appointment Term:** 5 years ending in 2031. * **Drug License Acquisition Date:** July 15, 2025 ## What to track next Investors will be keen to observe the utilization of the proposed inter-corporate loans and the performance of the new pharmaceutical trading venture. The company's ability to manage related party transactions and navigate market risks will also be critical.
